Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHEIN GENERIC METOPROLOL LAUNCH MUST BE DELAYED

Executive Summary

SCHEIN GENERIC METOPROLOL LAUNCH MUST BE DELAYED until the expiration date of Ciba-Geigy's Lopressor patent is determined in court, FDA told the generic manufacturer in a Feb. 8 approval letter. The approval of Schein's metoprolol marks the first time the agency has approved an ANDA without making an initial determination on the patent expiration date of the innovator product. Schein Pharmaceutical received prospective approval for both 50 mg and 100 mg generic metoprolol tablets. Lopressor is Ciba-Geigy's top-selling product in the U.S., with sales in the $ 150-200 mil. range. According to FDA's "Orange Book," Ciba-Geigy has two patents for Lopressor, one expiring in April 1992 and another expiring in December 1993. Schein challenged the patent expiration date in December 1986 and notified Ciba-Geigy and AB Hassle. Hassle is a subsidiary of the Swedish firm Astra and owns the product and use patents for metoprolol. Ciba-Geigy and Hassle subsequently filed a patent infringement suit against Schein on Jan. 21, 1987 in the New York Federal Court. Last February Schein requested that pretrial procedures be postponed while the firm's counsel prepared another patent challenge -- against Merck's Flexeril patent -- for Schein's subsidiary Danbury. Briefs in that case have been filed in the Court of Appeals for the Federal Circuit. In its response, Ciba-Geigy and Hassle agreed to postpone the litigation with the understanding that Schein will not market metoprolol before there is a final decision in the case. The brief states that Schein "hereby consents to the entry of an appropriate order by this court . . . lengthening the 30-month period until such time as a final decision in this case is rendered, during which period ]FDA[ may not make effective any approval of defendant's pending ANDA for metoprolol." The metoprolol patent infringement case is slated to go to trial on May 15, Schein said.(ITEM 200)#050928M001J59307# #970804M001XFCWP5# (ITEM 201)(COPYRIGHT) 1989 F-D-C Reports, Inc., The Pink Sheet, February 20, 1989

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel